Search This Blog

Friday, June 6, 2025

UroGen closes up 43% ahead of FDA decision on bladder cancer candidate

 UroGen Pharma (NASDAQ:URGN) closed Friday up ~43%, a week before the U.S. FDA is set to act on its NDA for UGN-102 (mitomycin)

https://seekingalpha.com/news/4456345-urogen-closes-up-43-ahead-of-fda-decision-on-bladder-cancer-candidate

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.